CLINICAL TRIALS PROFILE FOR RAPAFLO
✉ Email this page to a colleague
All Clinical Trials for RAPAFLO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00224107 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
NCT00224120 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
NCT00224133 ↗ | The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months | Completed | Watson Pharmaceuticals | Phase 3 | 2005-09-01 | A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RAPAFLO
Condition Name
Clinical Trial Locations for RAPAFLO
Trials by Country
Clinical Trial Progress for RAPAFLO
Clinical Trial Phase
Clinical Trial Sponsors for RAPAFLO
Sponsor Name